Secukinumab vs Ixekizumab: side effects in FDA adverse event reports
At a glance
| Secukinumab | Ixekizumab | |
|---|---|---|
| Drug class | Interleukin-17A Antagonist | Interleukin-17A Antagonist |
| Brand names | Cosentyx | Taltz |
| FAERS reports | 160,389 | 36,769 |
| Serious | 40% | 21% |
| Death outcome | 8,611 | 547 |
| Boxed warning | No | No |
Signals both drugs share
| Reaction | Secukinumab | Ixekizumab | Label screen (A / B) |
|---|---|---|---|
| Psoriatic arthropathy | 10,208 · PRR 44.3 | 791 · PRR 11.4 | Likely indication confounding / Likely indication confounding |
| Enthesopathy | 451 · PRR 52.2 | 55 · PRR 20.6 | Likely indication confounding / Not in label — unassessed |
| Rebound psoriasis | 389 · PRR 260.7 | 11 · PRR 10.9 | Likely indication confounding / Likely indication confounding |
| Dactylitis | 288 · PRR 54.1 | 34 · PRR 20.4 | Not in label — unassessed / Not in label — unassessed |
| Nail psoriasis | 179 · PRR 53.2 | 16 · PRR 15.1 | Likely indication confounding / Likely indication confounding |
Labeled signals distinctive to Secukinumab
- None stood out among the strongest labeled signals.
Labeled signals distinctive to Ixekizumab
- Injection site erythema — n=2,200, PRR 10.3 Labeled (related wording)
- Injection site reaction — n=1,785, PRR 15.2 Labeled adverse reaction
- Injection site swelling — n=1,650, PRR 12.7 Labeled (related wording)
- Injection site urticaria — n=670, PRR 16.2 Labeled (related wording)
- Injection site rash — n=544, PRR 10.4 Labeled (related wording)
- Injection site warmth — n=497, PRR 14.1 Labeled (related wording)
- Injection site hypersensitivity — n=77, PRR 14.6 Labeled (related wording)
- Injection site cellulitis — n=44, PRR 13.9 Labeled (related wording)
Common questions
Which has more reported side effects, Secukinumab or Ixekizumab?
Secukinumab has 160,389 FAERS reports and Ixekizumab 36,769. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (40% vs 21%) is a better like-for-like signal of the kind of problems reported.
Which side effects do Secukinumab and Ixekizumab share?
Both drugs carry disproportionality signals for psoriatic arthropathy, enthesopathy, rebound psoriasis, dactylitis, nail psoriasis. Shared signals often reflect a shared drug class or the condition both are used for.
Is Secukinumab or Ixekizumab safer?
FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.